What the name refers to
Purified nucleotide polymers marketed as injectable skin treatments, with evidence and regulatory classification varying widely by product and country.
Evidence and regulatory context
The broad ingredient name is not enough to determine approval. Regulatory status belongs to the exact finished product, formulation, intended use and jurisdiction.
Reading product records
Authorisation often belongs to a particular branded formulation, device, indication and professional setting—not to a broad ingredient name. Records should emphasise manufacturer, market-specific approval, batch, cold-chain or storage requirements and supply-chain provenance.
Primary research links
Use current regulator and study records rather than treating a catalogue description as medical evidence.